Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies

Title: Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies

Volume: 5 Issue: 1

Author(s): Maria Fernanda Garcia, Ximena Camacho, Victoria Calzada, Marcelo Fernandez, Williams Porcal, Omar Alonso, Juan Pablo Gambini and Pablo Cabral

Affiliation:

Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor

Abstract: The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher^® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [^99mTc(CO)₃(H₂O)₃]⁺ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. ^99mTc(CO₃)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of ^99mTc(CO₃)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.

Cite this article as:

Fernanda Garcia Maria, Camacho Ximena, Calzada Victoria, Fernandez Marcelo, Porcal Williams, Alonso Omar, Pablo Gambini Juan and Cabral Pablo, Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010059